External open innovation partner programNovel drug targets and compounds for the treatment of psychiatric and neurologic diseases
According to OMS, hundreds of millions of people worldwide are affected by psychiatric and neurologic disorders. With the extension of life expectancy and the ageing of the general populations in both developed and developing countries, the prevalence of these diseases are likely to increase.
We are looking for proposals to identify novel molecular targets or compounds for the treatment of bipolar disorders, schizophrenia or Parkinson’s disease.
Early Phase compounds up to PoC (Phase II clinical trials). The targets and/or the compounds must be innovative, with clinical relevance. Strong and high quality deriving from in vitro, ex vivo, animal models, and human data, strongly supporting the rationale and the druggability are required.
All proposals will be assessed by our Research & Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.
Proponents that submit proposals of interest will be contacted within 4 weeks of submission to clarify additional details.
Submit your proposal online (it takes about 15 minutes) in a form and length that is sufficient to provide the substance of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project and how that knowledge could be supplemented (i.e., what is additionally required to complete the project).
The Company will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.
If your proposal is selected, the Company is open to complete a Confidentiality Disclosure Agreement (CDA).
Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.
The Company is a privately owned international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical and mass-market sectors. Its pharmaceutical products are available in more than 50 countries through its branches and through an extensive network of licensees and strategic agreements with pharmaceutical companies and academic institutions.
The Company is currently engaged in research projects in the field of pain and inflammation disorders, nervous system diseases and disorders, and infection control and infectious diseases.
The activities are conducted in-house, and at principal public and private institutions either in partnership or in collaboration with leading scientists worldwide.
Biowebspin is the leading life sciences network with more than 2 million researchers in Biotech, Pharma and Medtech. Biowebspin has a database of 50,000 organizations working on 5000 different R&D projects in more than 50 topics, organized in 10 main types of partnering programs with Academia.